Navigation Links
Pieris Reports Preclinical Development Progress of its Next Generation VEGF Antagonist
Date:10/9/2009

FREISING-WEIHENSTEPHAN, Germany, October 9 /PRNewswire/ -- Pieris AG, the biopharmaceutical company developing Anticalins as a novel class of targeted human protein therapeutics, today reported continued progress in development of its lead therapeutic program for the clinic.

Under its manufacturing agreement with Wacker Biotech GmbH, a full-service contract manufacturer of biopharmaceuticals, Pieris has successfully completed the first cGMP run of its Anticalin candidate PRS-050, a potent VEGF antagonist with broad therapeutic applicability.

Having established production process parameters for PRS-050 earlier in 2009, Pieris has now met all regulatory CMC requirements to file an IND application by the end of January 2010. With toxicology studies running concurrently, PRS-050 is scheduled to commence first in man studies in the first half of 2010. Progress in the PRS-050 program demonstrates that Anticalin discovery programs can be successfully advanced from lead candidate to GMP production in around twelve months.

Commenting on these developments at Pieris, Claus Schalper, interim-CEO, said: "Sustained progress in development of PRS-050 underscores our commitment to advancing our lead Anticalin program into the clinic as quickly and efficiently as possible. This is in line with Pieris' strategy to bring Anticalins into the clinics while partnering selected project at an earlier development stage."

About Pieris AG

Pieris is a biopharmaceutical company engaged in the discovery and development of Anticalins, a novel class of targeted human proteins designed to diagnose and treat serious human disorders. Exploiting extensive know-how in protein engineering as part of a broad intellectual property portfolio, the company applies a balanced risk business model to the development of Anticalin product candidates.

About Anticalin Technology

Anticalins a
'/>"/>

SOURCE Pieris AG
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Pieris AG Enters into Anticalin Collaboration With Allergan, Inc.
2. Pieris Raises EUR 25 M (US$ 38 M) in Series B Financing Round
3. Pieris Validates the Use of Anticalins(R) as Ophthalmologic Biotherapeutics
4. Peregrine Pharmaceuticals Reports Positive Results From Phase II Bavituximab Lung Cancer Trial
5. Tianyin Pharmaceutical Co., Inc. Reports Record Fiscal 2009 Financials With $7.9 Million in Net Income
6. Neogen Reports 18% Increase in Net Income, 12% Increase in Revenues
7. Sinobiopharma Reports Highlights From Audited Financial Results for the Fiscal Year Ended May 31, 2009
8. Economic Strength of Hawaii Seed Crop Industry Confirmed by Recent Reports
9. Anpath Group, Inc. Reports Progress in Japanese Market
10. Micromet Reports Interim Data from Phase 1 Study of BiTE Antibody MT110 for the Treatment of Solid Tumors
11. YM BIOSCIENCES REPORTS NIMOTUZUMAB APPROVED FOR MARKETING IN MEXICO
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... (PRWEB) September 02, 2014 Myriant ... the signage of a distribution agreement with Azelis ... now distributing Myriant’s bio-succinic acid in the Nordics, ... Ireland, targeting customers in the industrial and base ... powerhouse, Azelis offers a far-reaching chemical portfolio with ...
(Date:9/2/2014)... MONROVIA, Calif. , Sept. 2, 2014 /PRNewswire/ ... clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for ... diseases, and cancer, today announced the appointment of ... clinical development and the appointment of Lloyd ... and general counsel. "Debra,s expertise ...
(Date:9/2/2014)... ON , Sept. 2, 2014 /PRNewswire/ - BIOREM Inc. (TSXV: ... totalling $2.1 million. The orders consist of three large odour ... Canada . "These orders are consistent with ... said Peter Bruijns , President and CEO. "After a ... market, we are now beginning to see sales growth. Our ...
(Date:9/2/2014)... , September 2, 2014 ... BioData,s research and lab management services  BioData, ... service, is pleased to announce the appointment of ... most recently served as VP Marketing and Business Development ... science research and clinical applications. Previously, Culot ...
Breaking Biology Technology:Myriant and Azelis Sign European Distribution Agreement for Bio-Succinic Acid 2Xencor Appoints Debra Zack, M.D., Ph.D., Vice President, Clinical Development and Lloyd Rowland, Senior Vice President, Chief Compliance Officer and General Counsel 2Xencor Appoints Debra Zack, M.D., Ph.D., Vice President, Clinical Development and Lloyd Rowland, Senior Vice President, Chief Compliance Officer and General Counsel 3Louis Culot Appointed as BioData's CEO 2
... 25 /Xinhua-PRNewswire-FirstCall/ -- 3SBio Inc.,(Nasdaq: SSRX ... researching,developing, manufacturing and marketing biopharmaceutical products,primarily in ... with the Chinese,State Food and Drug Administration ... formulation of EPIAO for the treatment of ...
... be Used for Advancement of Cancer Stem Cells and Other ... ... Inc., a privately,held biotechnology company that develops immunotherapeutics to treat,autoimmune disorders, ... in a Series D-2 financing. The round, led by,Nextech Venture, included ...
... COLLINS, Colo., Sept. 24 InVitria,( http://www.InVitria.com ... Annual "Optimizing Cell Culture Development" Conference on,September ... most recent,results optimizing cell culture media using ... ingredients.,( http://www.healthtech.com/ocb/overview.aspx?c=562 ), In a presentation ...
Cached Biology Technology:3SBio Inc. Files for SFDA Approval of High-dose (36,000 IU) EPIAO 23SBio Inc. Files for SFDA Approval of High-dose (36,000 IU) EPIAO 3MacroGenics Raises $25M in Series D-2 Financing 2MacroGenics Raises $25M in Series D-2 Financing 3MacroGenics Raises $25M in Series D-2 Financing 4InVitria Touts Product Advantages at Cambridge's Cell Culture Conference 2
(Date:9/2/2014)... Taiyuan, China, have substantially improved the health of people ... in costs associated with loss of life and disability ... Columbia Center for Children,s Environmental Health (CCCEH) at the ... the Center of Diseases Control and Prevention of Taiyuan ... , The study is the first to document the ...
(Date:9/2/2014)... DURHAM, N.C. -- When you accidentally touch a hot ... know the basic neural circuits involved in sensing and ... out the molecular players. , Duke researchers have made ... molecule involved in pain in worms, and have built ... Sept. 2 in Nature Communications , may help ...
(Date:9/1/2014)... Dietary quality in the U.S. has improved steadily in ... intakebut overall dietary quality remains poor and disparities continue ... a new study from Harvard School of Public Health ... to date that the extensive efforts by many groups ... some payoff, but it also indicates that these efforts ...
Breaking Biology News(10 mins):Clean air halves health costs in Chinese city 2Surprising new role for calcium in sensing pain 2Surprising new role for calcium in sensing pain 3Quality of US diet shows modest improvement, but overall remains poor 2Quality of US diet shows modest improvement, but overall remains poor 3
... what you know often comes at the price of learning ... easy for many, but not for those with conditions such ... simple routines. Using brain scans in monkeys, Duke ... monkeys will switch from exploiting a known resource to exploring ...
... Taylor Chair of Chemistry Barry Dellinger was recently awarded a ... Health Sciences, or NIEHS, to support a Superfund Research Center ... health. It is the only center ever awarded by this ... school of public health. "This grant is the result of ...
... semi-decayed vegetation matter, has been used by commercial growers ... century. Peat is added to potting soil to help ... for peat grew, acres of peat bogs were being ... of extracting peat from wetlands are mounting. And as ...
Cached Biology News:Monkey brains signal the desire to explore 2LSU receives $3.6 million to fund center studying hazardous waste cleanup and health impacts 2For peat's sake: Alternative growing media 2
... sealed isolation chamber provides a safe, ... sterile pharmaceuticals, in accord with USP-797 ... 100 (ISO 5) cleanliness conditions in ... IV rod and tilt-up front panel ...
... Protein determined by Biuret. Physical ... (NH 4 ) 2 SO ... Note: Affinity purified • Physical ... Additives: MgCl 2 1 ...
Ideal for chemical processing that requires downward flow of exhaust fumes. Powderful 1200 CFM blower draws fumes into sub-surface bonded charcoal filter for safe removal of organic vapors (final HEP...
... using mass numbers as a trigger, precisely ... performing investigation and research of natural compounds. ... and preparative operation. Switching between modes is ... This support provides a quick solution for ...
Biology Products: